By Josh Beckerman
Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment.
The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year.
The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy.
A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally.
"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4," the company said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 21, 2025 14:41 ET (19:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。